DrugPatentWatch Database Preview
Investigational Drug Information for Lucitanib
Email this page to a colleague
What is the drug development status for Lucitanib?
Lucitanib is an investigational drug.
There have been 9 clinical trials for Lucitanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are Clovis Oncology, Inc., Bristol-Myers Squibb, and Institut de Recherches Internationales Servier.
There are fifty-eight US patents protecting this investigational drug and four hundred and two international patents.
Summary for Lucitanib
| US Patents | 58 |
| International Patents | 402 |
| US Patent Applications | 175 |
| WIPO Patent Applications | 144 |
| Japanese Patent Applications | 51 |
| Clinical Trial Progress | Phase 2 (2019-11-14) |
| Vendors | 39 |
Recent Clinical Trials for Lucitanib
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Clovis Oncology, Inc. | Phase 1/Phase 2 |
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Eli Lilly and Company | Phase 1/Phase 2 |
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Exelixis | Phase 1/Phase 2 |
Clinical Trial Summary for Lucitanib
Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib
US Patents for Lucitanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Lucitanib | ⤷ Try it Free | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try it Free |
| Lucitanib | ⤷ Try it Free | Human anti-VEGFR-2/KDR antibodies | KADMON CORPORATION, LLC (New York, NY) | ⤷ Try it Free |
| Lucitanib | ⤷ Try it Free | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try it Free |
| Lucitanib | ⤷ Try it Free | Gene fusions and gene variants associated with cancer | LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) | ⤷ Try it Free |
| Lucitanib | ⤷ Try it Free | Rho kinase inhibitors | KADMON CORPORATION, LLC (New York, NY) | ⤷ Try it Free |
| Lucitanib | ⤷ Try it Free | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lucitanib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Lucitanib | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Try it Free |
| Lucitanib | Canada | CA2926386 | 2032-10-05 | ⤷ Try it Free |
| Lucitanib | China | CN105007939 | 2032-10-05 | ⤷ Try it Free |
| Lucitanib | China | CN109160950 | 2032-10-05 | ⤷ Try it Free |
| Lucitanib | Eurasian Patent Organization | EA032679 | 2032-10-05 | ⤷ Try it Free |
| Lucitanib | Eurasian Patent Organization | EA201500363 | 2032-10-05 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
